Your Cart
TARGETING THE KEY
MECHANISMS
RESPONSIBLE FOR THE
CELLULAR AND MOLECULAR
MANIFESTATIONS
OF NEURONAL AGING
DEVELOPMENT PIPELINE
We are developing multi-therapeutics that focus on the central nervous system. Our research programs aim to explore the potential of our scientific discovery in addressing a broad range of inflammatory-based brain health concerns.
CLINICAL STUDIES
Our clinical research programs focus on evaluating the scientific efficacy of our neuroprotective compounds and plays a vital role in helping advance the field of brain health.
PILOT STUDY ON COGNITIVE BENEFITS OF EDGE™
Status: In Progress
Enrollment: Closed
To learn more about our pilot study on REVIVE™ contact: researchteam@senescence.life.
PILOT STUDY ON COGNITIVE BENEFITS OF REVIVE™
Status: In progress
Enrollment: Closed
To learn more about our pilot study on REVIVE™ contact: researchteam@senescence.life.
Clinical trial on mild cognitive impairment
Status: planning
We anticipate trial initiation for our mild cognitive impairment trials in Q1 2019.
To learn more about our mild cognitive impairment trials contact: researchteam@senescence.life.
Clinical trial on early stage Alzheimer's Disease
Status: planning
We anticipate trial initiation for our early stage Alzheimer’s disease trials in Q1 2019.
To learn more about our early stage Alzheimer's disease trials contact: researchteam@senescence.life.
Pilot study on Post-traumatic stress disorder
Status: Enrolling
We are currently enrolling individuals diagnosed with post-traumatic stress disorder (PTSD) to test the therapeutic potential of NeuroSHIELD™ in alleviating symptoms of PTSD.
To learn more about our PTSD study contact: researchteam@senescence.life.
pilot study on decision fatigue
Status: R&D
We anticipate trial initiation for our decision fatigue study in Q3 2019.
To learn more about our decision fatigue study contact: researchteam@senescence.life.